Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of S086 tablets for mild to moderate essential hypertension
ChiCTR2000036014Phase 2Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Aug 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of S086 in essential hypertension (3 arms), sponsored by Ruijin Hospital. Primary endpoint: Systolic blood pressure. Planned start Aug 2020; status: not yet recruiting.
02
Drugs
S086
03
Conditions
essential hypertension
Beyond the preview
Go deeper on ChiCTR2000036014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000036014.